Indaptus Therapeutics provides a clinical update on the ongoing INDP-D101 trial, highlighting positive outcomes and progress in their Decoy platform.
Decoy20 monotherapy shows promise in treating urothelial cancer and liver metastases, with a patient demonstrating a partial response.
Combination therapy of Decoy20 with tislelizumab exhibits favorable safety profiles and ongoing evaluation in the trial.
Partial Response in Monotherapy
Clear reduction in liver metastases observed in a patient receiving Decoy20 monotherapy.
Combination Therapy Update
Initial safety cohort for combination therapy initiated with stable disease and progression observed in evaluated patients.
Financial Update
$5.7 million raised through convertible promissory notes, strengthening the company's balance sheet for future trials.
- Decoy platform shows potential as a breakthrough therapy in combination with tislelizumab, with positive responses in the trial.
- Financial raise provides support for continued development and execution of clinical trials.
- Promising results in monotherapy and ongoing evaluation of combination therapy signal advancements in cancer treatment approaches.
Indaptus Therapeutics continues to advance its Decoy platform in cancer treatment, emphasizing safety and efficacy in clinical trials. The positive outcomes in monotherapy and initial results in combination therapy showcase potential for innovative treatment options.